Bone Abstracts

Introduction: Granulocyte colony-stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells (PBSC) and enable PBSC collection by apheresis. Although bone pain is a common adverse event following G-CSF treatment, little is known on its effect on bone metabolism.Methods: Markers of bone turnover (OC, osteocalcin, β-CTx, bALP, C-terminal telopeptide of type I collagen, bone specific alkaline phosphatase, TRAP, tartrate resistant ...

Biographical DetailsCecilia GötherströmCecilia Götherström is Associate Professor in Stem Cell Research at Karolinska Institutet and her research is in the field of perinatal regenerative medicine. She was one of the first in the world to isolate and characterize human fetal mesenchymal stem cells. Dr Götherström has de...

Osteogenesis imperfecta (OI) type V is caused by a unique dominant mutation (c.−14C>T) in IFITM5, which encodes BRIL, a transmembrane ifitm-like protein most strongly expressed in osteoblasts, while type VI OI is caused by recessive null mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). We identified a 25-year-old woman with severe OI, whose dermal fibroblasts and cultured osteoblasts displayed minimal secretion of PEDF, but ...

Background and methods: Pigment epithelium-derived factor (PEDF) is a potent antiangiogenic factor, ubiquitously expressed and secreted in human tissues. Hypertrophic cartilage and osteoblasts express PEDF that binds to type I collagen and glycosaminoglycans in the extracellular matrix. Two rare forms of osteogenesis imperfecta (OI) with intact collagen synthesis are associated with PEDF deficiency. Histological observations revealed excessive osteoid formation and prolonged m...

Mutations in the C-propeptide cleavage site of both COL1A1 and COL1A2 cause dominant high bone mass (HBM) osteogenesis imperfecta (OI), characterized by bone hypermineralization. To elucidate the role of C-propeptide processing in bone formation, we generated heterozygous HBM mice in which both residues of the COL1A1 cleavage site were mutated to prevent cleavage by BMP1. HBM mice are smaller than WT in both weight and length and have extremely brittle bones....

High Bone Mass (HBM) osteogenesis imperfecta (OI) is caused by dominant mutations in the C-propeptide cleavage site of COL1A1 or COL1A2, characterized by bone hypermineralization. To elucidate the role of C-propeptide processing in bone mineralization and development, we generated heterozygous HBM mice with both residues (Ala-Asp) of the COL1A1 cleavage site substituted (Thr-Asn) to prevent processing by BMP1. Two, 6- and 12-month WT and HBM bones were examin...

Aim: Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS) is an invasive treatment able to control local disease and pain of bone tumors. Unfortunately, there is not any scientific evidence of the biological effect of MRgFUS treatment on tumor cells, especially in lower dose region, where tissues are only warmed to sub-lethal temperatures. Here we investigate the effect of in vitro MRgFUS treatment, at different levels of acoustic energy (200–630 J), on ...

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...

Introduction: Dual X-ray Absorptiometry (DXA) is currently the best technique available to evaluate bone mass, enabling the diagnosis of osteoporosis, the prediction of fracture risk and monitoring.Clinical good practices consider as preferred measuring sites the lumbar (L1–L4) and proximal femur (neck and total). The vertebral morphometry is a quantitative method for the diagnosis of vertebral fractures based on measuring vertebral heights.<p...